New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 17, 2014
16:10 EDTAMGNAmgen announces positive Phase 3 results for AMG 416
Amgen announced that a Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism, or SHPT, in patients with chronic kidney disease, or CKD, receiving hemodialysis, met its primary and all secondary endpoints. The primary endpoint was the proportion of patients with greater than 30% reduction from baseline in parathyroid hormone, or PTH, levels during an Efficacy Assessment Phase, or EAP, defined as the period between weeks 20 and 27. Amgen obtained AMG 416 as part of the acquisition of KAI Pharmaceuticals, Inc. in July 2012 and these are the first results to be reported from the Phase 3 program. In the AMG 416 group, 75.3% of patients achieved a greater than 30% reduction from baseline in PTH compared with 9.6% in the placebo arm, a statistically significant result. Secondary endpoints included the percent change from baseline during the EAP in serum phosphorus concentration and corrected calcium concentration. Both of these secondary endpoint results were statistically significant.
News For AMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 1, 2015
14:42 EDTAMGNPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information
March 30, 2015
09:02 EDTAMGNAmgen says FDA grants priority review for Kyprolis sNDA
Subscribe for More Information
March 26, 2015
06:45 EDTAMGNBiotech valuation concerns 'misguided,' says Piper Jaffray
Subscribe for More Information
March 24, 2015
09:10 EDTAMGNDako announces collaboration agreement with Amgen
Dako, an Agilent Technologies (A) company, announced a new Master Collaboration Agreement with Amgen (AMGN). The expanded collaboration will allow both companies to benefit from knowledge-sharing within the field of drug-diagnostic research and development in general, and in relation to companion diagnostic products in particular. The financial details of the agreement were not disclosed.
March 23, 2015
12:10 EDTAMGNTeva migraine drug data positive for Amgen, says Piper Jaffray
Piper Jaffray said the "positive" trial data Teva (TEVA) reported for its anti-CGRP antibody in migraines is another important validation for the class of drugs that is also being worked on by Amgen (AMGN), Eli Lilly (LLY) and Alder Biopharmaceuticals (ALDR). The firm said it thinks Amgen is one of the leaders in CGRP antibody space and reiterated its Overweight rating and $187 price target on Amgen shares.
09:03 EDTAMGNLeerink analysts hold a meeting with a conference call hookup
Subscribe for More Information
March 20, 2015
09:06 EDTAMGNAmgen submits application for marketing approval for RepathaTM in Japan
Subscribe for More Information
07:41 EDTAMGNAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information
March 19, 2015
15:55 EDTAMGNAmgen injunction bid for Neupogen biosimilar denied, Reuters reports
Subscribe for More Information
15:13 EDTAMGNAmgen denied preliminary injunction for biologics against Novartis, Reuters says

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use